Abstract Library

#3603 Genetic tumor and blood profiling in the randomised controlled phase III COMPOSE trial comparing 177Lu-edotreotide and best standard of care for well-differentiated aggressive grade 2/3 gastroenteropancreatic neuroendocrine tumors

Introduction: COMPOSE is a randomised, controlled, open-label, Phase III trial in patients with well-differentiated aggressive G2/G3 (Ki-67 index 15−55%), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 177Lu-edotreotide targeted radionuclide therapy (TRT) will be compared with best standard of care (CAPTEM, FOLFOX or everolimus). Therapeutic strategies for high grade GEP-NETs demonstrate variable outcomes and currently there is a lack of tools to predict TRT efficacy and disease progression. Genetic profiling analysis is proposed to address this need.

Conference:

Presenting Author:

Authors: Capdevila J, Halfdanarson T, Halperin D, Herrmann K, Kong G,

Keywords: gastroenteropancreatic neuroendocrine tumor, targeted radionuclide therapy, bioinformatics, gene expression,

#3430 Comprehensive transcriptomic and methylomic analysis of NENs from multiple origins show subgroups of patients with clinical relevance

Introduction: Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors with a wide anatomical distribution that share common neuro and endocrine properties. Although some studies have assessed the NET molecular landscape of certain primary sites, none of them have evaluated cross-sites molecular studies.

Conference:

Presenting Author: Carretero C

Authors: Carretero C, Soldevilla B, Gil B, La Salvia A, Lens-Pardo A,

Keywords: neuroendocrine tumor, multiomics, subtypes,

#3183 Clinical stratification of pancreatic neuroendocrine tumors by systematically integrating multimodal and clinical data

Introduction: Non-functional pancreatic neuroendocrine tumors (PanNETs) are heterogeneous with at least two transcriptome subtypes with differential biology, immune mechanisms and prognosis. However, it is challenging to understand how multimodal data interact with clinical variables and contribute to the disease heterogeneity and phenotypes.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Lawlor R, Mafficini A, Luchini C, Nyamundanda G,

Keywords: pancreatic neuroendocrine tumor, multimodal data integration, multiomics, clinical data integration, machine learning, artificial intelligence, subtypes, pancreatic cancer, phenotypes, PhenMap, mutations, gene expression, microRNA,

#2896 Comparative Genomic Analysis of High Grade Neuroendocrine Neoplasms across Diverse Organs

Introduction: Grade 3 neuroendocrine neoplasms (G3 NENs), if poorly differentiated, have a median survival of 10-19 months. Little is known regarding biologic differences between G3 NENs from different primary sites, most commonly GI and lung.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sun T

Authors: Sun T, Van Hummelen P, Martin B, Xia C, Zhao L,

Keywords: grade 3, high grade, neuroendocrine carcinoma, whole exome sequencing, rna-seq, transcriptomics, copy number analysis, sequencing, genomics, poorly differentiated,